Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Role of maternal factors in autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 November.
Role of maternal factors in autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 November.
Neurophysiology data-sharing system faces funding cliff
After the primary grant supporting Neurodata Without Borders ends in March 2026, the platform may no longer be maintained or kept up to date.
Neurophysiology data-sharing system faces funding cliff
After the primary grant supporting Neurodata Without Borders ends in March 2026, the platform may no longer be maintained or kept up to date.
A change at the top of SfN as neuroscientists gather in San Diego
Kevin B. Marvel, longtime head of the American Astronomical Society, will lead the Society for Neuroscience after a year of uncertainty in the neuroscience field.
A change at the top of SfN as neuroscientists gather in San Diego
Kevin B. Marvel, longtime head of the American Astronomical Society, will lead the Society for Neuroscience after a year of uncertainty in the neuroscience field.